Market Cap | 608.14M | P/E | - | EPS this Y | 54.50% | Ern Qtrly Grth | - |
Income | -156.83M | Forward P/E | -3.15 | EPS next Y | 10.00% | 50D Avg Chg | 28.00% |
Sales | 2.06B | PEG | -0.23 | EPS past 5Y | - | 200D Avg Chg | 17.00% |
Dividend | N/A | Price/Book | 1.88 | EPS next 5Y | 19.10% | 52W High Chg | -65.00% |
Recommedations | 2.70 | Quick Ratio | - | Shares Outstanding | 406.79M | 52W Low Chg | 78.00% |
Insider Own | 7.64% | ROA | - | Shares Float | 376.06M | Beta | - |
Inst Own | 24.68% | ROE | - | Shares Shorted/Prior | 48.16M/47.54M | Price | 1.26 |
Gross Margin | 14.21% | Profit Margin | -7.77% | Avg. Volume | 9,555,241 | Target Price | 1.44 |
Oper. Margin | -6.44% | Earnings Date | Aug 6 | Volume | 4,576,438 | Change | -3.08% |
Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat. Clover Health Investments, Corp. was incorporated in 2014 and is based in Franklin, Tennessee.
Citigroup | Neutral | Aug 11, 23 |
Canaccord Genuity | Buy | Mar 6, 23 |
Credit Suisse | Underperform | Mar 6, 23 |
Citigroup | Neutral | Nov 16, 22 |
SVB Leerink | Market Perform | Nov 8, 22 |
Citigroup | Neutral | Aug 9, 22 |
Credit Suisse | Underperform | Aug 9, 22 |
SVB Leerink | Market Perform | May 10, 22 |
SVB Leerink | Market Perform | Feb 25, 22 |